Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity

v3.23.2
Stockholders' Equity
12 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Stockholders' Equity

17. STOCKHOLDERS’ EQUITY

Shelf Registration Statement

On September 25, 2020, the Company filed a universal shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission (the “SEC”) on March 4, 2021, on which the Company registered for sale up to $150.0 million of any combination of its debt securities, shares of common stock, shares of preferred stock, rights, warrants, units and/or purchase contracts from time to time and at prices and on terms that the Company may determine. After a public offering of common stock in March 2021, approximately $69.5 million of securities remain available for issuance under this shelf registration statement. Securities may be offered or sold under this registration statement until March 2024.

Dividends

On August 18, 2022, the Company's board of directors declared a non-recurring special dividend of $1.00 per common share to stockholders of record at the close of business on September 12, 2022. The dividend was paid on September 26, 2022 and totaled $23.4 million.

On August 18, 2022, the Company's board of directors also declared the initial quarterly regular cash dividend of $0.20 per common share to stockholders of record at the close of business on October 10, 2022. The dividend was paid on October 24, 2022 and totaled $4.7 million.

On January 4, 2023, the Company's board of directors declared a regular dividend of $0.20 per share to stockholders of record at the close of business on January 16, 2023. The dividend was paid on January 27, 2023 and totaled $4.7 million.

On April 5, 2023, the Company's board of directors declared a regular dividend of $0.20 per share to stockholders of record as of the close of business on April 17, 2023. The dividend was paid on April 28, 2023 and totaled $4.7 million.

Share Repurchase Program

In April 2018, the Company's board of directors approved a share repurchase program which authorized the Company to purchase up to 1,000,000 shares (as adjusted for the two-for-one split of A-Mark’s common stock in the form of a stock dividend in fiscal 2022) of its common stock. The share repurchase program was initially announced on May 8, 2018. In fiscal 2023, we repurchased a total of 335,735 shares under the program for $9.8 million. Late in fiscal 2023, the board revised the repurchase program to authorize the purchase of up to 1,000,000 shares of our common stock, in addition to the shares previously repurchased, and extended the expiration date from June 30, 2023 to June 30, 2028. Prior to fiscal 2023, no shares had been repurchased under our share repurchase program.

Under the share repurchase program, we may repurchase shares of our common stock from time to time at prevailing market prices, depending on market conditions, through open market or privately negotiated transactions. Subject to applicable corporate securities laws, repurchases may be made at such times and in amounts as management deems appropriate. We are not obligated to repurchase any shares under the program, and repurchases under the program may be discontinued if management determines that additional repurchases are not warranted.

2014 Stock Award and Incentive Plan

The Company's amended and restated 2014 Stock Award and Incentive Plan (the "2014 Plan") was approved most recently on October 27, 2022 by the Company's stockholders. As of June 30, 2023, 1,446,260 stock options and 92,957 restricted stock units were outstanding, and 1,727,894 shares were available for issuance of new awards under the 2014 Plan.

Under the 2014 Plan, the Company may grant options and other equity awards as a means of attracting and retaining officers, employees, non-employee directors and consultants, to provide incentives to such persons, and to align the interests of such persons with the interests of stockholders by providing compensation based on the value of the Company's stock. Awards under the 2014 Plan may be granted in the form of incentive or non-qualified stock options, stock appreciation rights ("SARs"), restricted stock, RSUs, dividend equivalent rights, other stock-based awards (which may include outright grants of shares) and cash incentive awards. The 2014 Plan also authorizes grants of awards with performance-based conditions and market-based conditions. The 2014 Plan is administered by the Compensation Committee of the board of directors, which, in its discretion, may select officers and other employees, directors (including non-employee directors) and consultants to the Company and its subsidiaries to receive grants of awards. The board of directors itself may perform any of the functions of the Compensation Committee under the 2014 Plan.

Under the 2014 Plan, the exercise price of options and base price of SARs, as set by the Compensation Committee, generally may not be less than the fair market value of the shares on the date of grant, and the maximum term of stock options and SARs is 10 years. The 2014 Plan limits the number of share-denominated awards that may be granted to any one eligible person in any fiscal year to 500,000 shares plus the participant's unused annual limit at the close of the previous year. Also, in the case of non-employee directors, the 2014 Plan limits the maximum grant-date fair value at $300,000 of stock-denominated awards granted to a director in a given fiscal year, except for a non-employee Chairman of the Board whose grant-date fair value maximum is $600,000 per fiscal year. The 2014 Plan will terminate when no shares remain available for issuance and no awards remain outstanding; however, the authority to grant new awards will terminate on October 27, 2032.

Stock Options

The Company measures the compensation cost of stock options using the Black-Scholes option pricing model, which uses various inputs such as the common share price and estimates that include the risk-free interest rate, volatility, expected life and dividend yield. The weighted-averages for key assumptions used in determining the fair value of options granted were as follows:

 

 

Year Ended June 30,

 

 

2023

 

2022

 

 

2021

Average volatility

 

47.96%

 

N/A (1)

 

 

41.76%

Risk-free interest rate

 

3.76%

 

N/A (1)

 

 

0.46%

Weighted-average expected life in years

 

6.0

 

N/A (1)

 

 

6.1

Dividend yield rate annual

 

2.10%

 

N/A (1)

 

 

0.0%

 

(1) Not applicable; no employee stock options were issued during the fiscal year ended June 30, 2022.

During the years ended June 30, 2023, 2022, and 2021, the Company incurred $1.2 million, $1.4 million and $1.1 million of compensation expense related to stock options, respectively. As of June 30, 2023, there was total remaining compensation expense of $0.8 million related to employee stock options, which will be recorded over a weighted average vesting period of approximately 1.1 years.

A required adjustment to outstanding stock options was triggered as a result of the non-recurring special dividend declared on August 18, 2022. In accordance with the terms of the Company’s equity award plans under which the options were issued, an adjustment was required to protect the holders of such stock options from decreases in the value of the stock options due to payment of the non-recurring special dividends. This event decreased the exercise price of outstanding stock options by $1.00 per option share, effective as of the ex-dividend date (September 9, 2022). The fair value of the options before and after this event was unchanged, and therefore no incremental stock-based compensation expense was recorded.

The following table summarizes the stock option activity for the years ended June 30, 2023, 2022, and 2021:

 

 

Options

 

 

Weighted Average Exercise Price Per Share

 

 

Aggregate
Intrinsic Value
(in thousands)

 

 

Weighted Average Grant Date Fair Value Per Award

 

Fiscal 2021

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at June 30, 2020

 

 

2,499,626

 

 

$

7.62

 

 

$

6,061

 

 

$

2.67

 

Granted

 

 

392,000

 

 

$

17.75

 

 

$

 

(1)

$

7.35

 

Exercises

 

 

(570,370

)

 

$

6.65

 

 

$

7,037

 

 

$

2.75

 

Cancellations, expirations and forfeitures

 

 

(3,200

)

 

$

9.33

 

 

$

 

 

$

3.49

 

Outstanding at June 30, 2021

 

 

2,318,056

 

 

$

8.01

 

 

$

35,343

 

 

$

3.44

 

Exercisable at June 30, 2021

 

 

1,385,302

 

 

$

6.88

 

 

$

22,675

 

 

$

2.89

 

Fiscal 2022

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at June 30, 2021

 

 

2,318,056

 

 

$

8.01

 

 

$

35,343

 

 

$

3.44

 

Exercises

 

 

(538,596

)

 

$

4.32

 

 

$

15,874

 

 

$

3.22

 

Cancellations, expirations and forfeitures

 

 

 

 

$

 

 

$

 

 

$

 

Outstanding at June 30, 2022

 

 

1,779,460

 

 

$

7.84

 

 

$

43,433

 

 

$

3.51

 

Exercisable at June 30, 2022

 

 

1,147,972

 

 

$

6.28

 

 

$

29,811

 

 

$

2.65

 

Fiscal 2023

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at June 30, 2022

 

 

1,779,460

 

 

$

7.84

 

 

$

43,433

 

 

$

3.51

 

Granted

 

 

10,000

 

 

$

39.69

 

 

$

 

(1)

$

16.56

 

Exercised

 

 

(343,200

)

 

$

6.68

 

 

$

8,562

 

 

$

3.57

 

Cancellations, expirations and forfeitures

 

 

 

 

$

 

 

$

 

 

$

 

Outstanding at June 30, 2023

 

 

1,446,260

 

 

$

7.11

 

 

$

43,882

 

 

$

3.58

 

Exercisable at June 30, 2023

 

 

1,175,591

 

 

$

5.02

 

 

$

38,505

 

 

$

2.53

 

 

(1) The Company issued the options with an exercise price per share not less than the closing market price of common stock on the grant date.

The following table summarizes information about stock options outstanding and exercisable as of June 30, 2023:

Exercise Price Ranges

 

 

Options Outstanding

 

 

Options Exercisable

 

From

 

 

To

 

 

Number of
 Underlying
 Shares

 

 

Weighted Average Remaining Contractual Life
(Years)

 

 

Weighted Average Exercise Price

 

 

Number of
 Underlying
 Shares

 

 

Weighted Average Remaining Contractual Life
(Years)

 

 

Weighted Average Exercise Price

 

$

 

 

$

5.00

 

 

 

704,658

 

 

 

6.24

 

 

$

1.90

 

 

 

704,658

 

 

 

6.24

 

 

$

1.90

 

$

5.01

 

 

$

7.50

 

 

 

49,600

 

 

 

2.86

 

 

$

6.37

 

 

 

49,600

 

 

 

2.86

 

 

$

6.37

 

$

7.51

 

 

$

12.50

 

 

 

426,668

 

 

 

2.93

 

 

$

8.86

 

 

 

400,000

 

 

 

2.64

 

 

$

8.83

 

$

12.51

 

 

$

30.00

 

 

 

255,334

 

 

 

7.69

 

 

$

17.42

 

 

 

21,333

 

 

 

7.48

 

 

$

14.77

 

$

30.01

 

 

$

50.00

 

 

 

10,000

 

 

 

9.60

 

 

$

39.69

 

 

 

 

 

 

 

 

$

 

 

 

 

 

 

 

1,446,260

 

 

 

5.43

 

 

$

7.11

 

 

 

1,175,591

 

 

 

4.90

 

 

$

5.02

 

The following table summarizes the nonvested stock option activity for the year ended June 30, 2023:

 

 

Options

 

 

 

Weighted Average Grant Date Fair Value Per Award

 

Nonvested outstanding at June 30, 2022

 

 

631,488

 

 

 

$

5.06

 

Granted

 

 

10,000

 

 

 

$

16.56

 

Vested

 

 

(370,819

)

 

 

$

3.13

 

Nonvested outstanding at June 30, 2023

 

 

270,669

 

 

 

$

8.14

 

Restricted Stock Units

RSUs granted by the Company are not transferable and automatically convert to shares of common stock on a one-for-one basis as the awards vest or at a specified date after vesting. RSUs granted to a non-US citizen are referred to as "deferred stock units" or "DSUs". The Company measures the compensation cost of RSUs based on the closing price of the underlying shares at the grant date.

A required adjustment to certain outstanding RSUs was triggered as a result of the non-recurring special dividend declared on August 18, 2022. In accordance with the terms of the 2014 Plan and the Company’s RSU agreements under which the RSUs were issued, the holders of the RSUs were entitled to credits equivalent to dividends that would have been paid if the RSUs had been outstanding shares as of the applicable record date (such credits being either in cash or additional RSUs). The fair values of these RSUs before and after the dividend payment dates were unchanged, and therefore no incremental stock-based compensation expense was recorded. RSUs also are credited with dividend equivalents when the Company pays regular dividends; these are cash credits that are paid upon settlement of the RSUs, except in the case of DSUs the dividend equivalents are converted into additional DSUs.

During the years ended June 30, 2023, 2022, and 2021, the Company incurred $0.9 million, $0.8 million and $0.1 million of compensation expense related to RSUs, respectively. As of June 30, 2023, there is $1.6 million remaining compensation expense related to RSUs, which will be recorded over a weighted average vesting period of approximately 2.0 years.

The following table summarizes RSU activity for the years ended June 30, 2023, 2022, and 2021:

 

 

Awards
Outstanding

 

 

 

Weighted Average Fair Value per Unit at Grant Date

 

 

Fiscal 2021

 

 

 

 

 

 

 

 

Nonvested outstanding at June 30, 2020

 

 

 

 

 

$

 

 

Granted

 

 

25,442

 

 

 

$

18.86

 

 

Nonvested outstanding at June 30, 2021

 

 

25,442

 

 

 

$

18.86

 

 

Fiscal 2022

 

 

 

 

 

 

 

 

Nonvested outstanding at June 30, 2021

 

 

25,442

 

 

 

$

18.86

 

 

Granted

 

 

56,205

 

 

 

$

32.51

 

 

Vested & delivered

 

 

(6,360

)

 

 

$

18.86

 

 

Vested & deferred (1)

 

 

(19,194

)

 

 

$

18.75

 

 

Nonvested outstanding at June 30, 2022

 

 

56,093

 

 

 

$

32.58

 

 

Vested but subject to deferred settlement at June 30, 2022 (1)

 

 

19,194

 

 

 

$

18.75

 

 

Outstanding at June 30, 2022

 

 

75,287

 

 

 

$

29.05

 

 

Fiscal 2023

 

 

 

 

 

 

 

 

Nonvested outstanding at June 30, 2022

 

 

56,093

 

 

 

$

32.58

 

 

Granted (2)

 

 

35,269

 

 

 

$

32.90

 

 

Vested & delivered

 

 

(17,599

)

 

 

$

32.34

 

 

Vested & deferred (1)

 

 

(10,176

)

 

 

$

35.36

 

 

Nonvested outstanding at June 30, 2023

 

 

63,587

 

 

 

$

32.37

 

 

Vested but subject to deferred settlement at June 30, 2023 (1)

 

 

29,370

 

 

 

$

24.50

 

 

Outstanding at June 30, 2023

 

 

92,957

 

 

 

$

29.89

 

 

 

(1) Certain RSU holders elected to defer settlement of the RSUs to a specified date. The DSU holder is contractually obligated to defer settlement of the DSUs to a specified date following the holder’s termination of service.

(2) Includes 9,397 RSUs that vest based on continuous employment and achievement of non-market performance goals through June 30, 2024, 2025 and 2026.

Common Stock

In fiscal 2023, a portion of the fiscal 2022 annual bonuses was paid in the form of common stock to the Chief Executive Officer and President. The Company issued 10,500 shares (in the aggregate) of common stock, after deducting 3,184 shares of common stock to satisfy tax withholding obligations relating to the President's award.

Certain Anti-Takeover Provisions

The Company’s certificate of incorporation and by-laws contain certain anti-takeover provisions that could have the effect of making it more difficult for a third-party to acquire, or of discouraging a third-party from attempting to acquire, control of the Company without negotiating with its board of directors. Such provisions could limit the price that certain investors might be willing to pay in the future for the Company’s securities. Certain of such provisions allow the Company to issue preferred stock with rights senior to those of the common stock or impose various procedural and other requirements which could make it more difficult for stockholders to effect certain corporate actions.